Hydrochlorothiazide Tablets

Total Page:16

File Type:pdf, Size:1020Kb

Hydrochlorothiazide Tablets HYDROCHLOROTHIAZIDE Edema during pregnancy may arise from patho­ irritability). Hypokalemia may be avoided or treated logic causes or from the physiologic and mechanical by use of potassium sparing diuretics or potassium TABLETS, USP consequences of pregnancy. Thiazides are indicated supplements such as foods with a high potassium 12.5 mg, 25 mg and 50 mg in pregnancy when edema is due to pathologic content. causes, just as they are in the absence of pregnan­ Although any chloride deficit is generally mild and cy (see PRECAUTIONS: Pregnancy). Dependent usually does not require specific treatment except edema in pregnancy, resulting from restriction of under extraordinary circumstances (as in liver dis­ DESCRIPTION: Hydrochlorothiazide is a diuretic venous return by the gravid uterus, is properly treat­ ease or renal disease), chloride replacement may and antihypertensive. It is the 3,4-dihydro derivative ed through elevation of the lower extremities and be required in the treatment of metabolic alkalosis. of chlorothiazide. It is chemically designated as 6­ use of support stockings. Use of diuretics to lower Dilutional hyponatremia may occur in edematous chloro-3,4-dihydro-2 H-1,2,4-benzothiadiazine-7-sul­ intravascular volume in this instance is illogical and patients in hot weather; appropriate therapy is water fonamide 1,1-dioxide and has the following structural unnecessary. During normal pregnancy there is restriction, rather than administration of salt, except formula: hypervolemia which is not harmful to the fetus or the in rare instances when the hyponatremia is life mother in the absence of cardiovascular disease. threatening. In actual salt depletion, appropriate However, it may be associated with edema, rarely replacement is the therapy of choice. generalized edema. If such edema causes discom­ fort, increased recumbency will often provide relief. Hyperuricemia may occur or acute gout may be Rarely this edema may cause extreme discomfort precipitated in certain patients receiving thiazides. which is not relieved by rest. In these instances, a In diabetic patients dosage adjustments of insulin short course of diuretic therapy may provide relief or oral hypoglycemic agents may be required. HCTZT:R2 and be appropriate. Hyper glycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest C7H8ClN3O4S2 M.W. 297.74 CONTRAINDICATIONS: Anuria. during thiazide therapy. Hydrochlorothiazide, USP is a white, or practically Hypersensitivity to this product or to other sulfon­ The antihypertensive effects of the drug may be white, crystalline powder which is slightly soluble in amide-derived drugs. enhanced in the post-sympathectomy patient. water, freely soluble in sodium hydroxide solution, in WARNINGS: Use with caution in severe renal dis­ If progressive renal impairment becomes evi­ n-butylamine, and in dimethylformamide; sparingly ease. In patients with renal disease, thiazides may dent, consider withholding or discontinuing diuretic soluble in methanol; insoluble in ether, in chloroform, precipitate azotemia. Cumulative effects of the drug therapy. and in dilute mineral acids. Each tablet for oral may develop in patients with impaired renal function. Thiazides have been shown to increase the uri­ administration contains 12.5 mg, 25 mg or 50 mg Thiazides should be used with caution in patients nary excretion of magnesium; this may result in hydrochlorothiazide, USP. In addition, each tablet with impaired hepatic function or progressive liver hypomagnesemia. contains the following inactive ingredients: colloidal disease, since minor alterations of fluid and elec­ Thiazides may decrease urinary calcium excre­ silicon dioxide, magnesium stearate, microcrystalline trolyte balance may precipitate hepatic coma. cellulose, pregelatinized starch, and sodium lauryl tion. Thiazides may cause intermittent and slight ele­ Thiazides may add to or potentiate the action of sulfate. vation of serum calcium in the absence of known other antihypertensive drugs. disorders of calcium metabolism. Marked hypercal­ CLINICAL PHARMACOLOGY: The mechanism of Sensitivity reactions may occur in patients with or cemia may be evidence of hidden hyperparathy­ the antihypertensive effect of thiazides is unknown. without a history of allergy or bronchial asthma. roidism. Thiazides should be discontinued before Hydrochlorothiazide does not usually affect normal The possibility of exacerbation or activation of sys­ carrying out tests for parathyroid function. blood pressure. temic lupus erythematosus has been reported. Increases in cholesterol and triglyceride levels Hydrochlorothiazide affects the distal renal tubular Lithium generally should not be given with diuret­ may be associated with thiazide diuretic therapy. mechanism of electrolyte reabsorption. At maximal ics (see PRECAUTIONS: Drug Interactions). Laboratory Tests: Periodic determination of serum therapeutic dosage all thiazides are approximately electrolytes to detect possible electrolyte imbalance equal in their diuretic efficacy. Acute Myopia and Secondary Angle-Closure Glaucoma: Hydrochlorothiazide, a sulfonamide, should be done at appropriate intervals. Hydrochlorothiazide increases excretion of sodi­ can cause an idiosyncratic reaction, resulting in Drug Interactions: When given concurrently the um and chloride in approximately equivalent acute transient myopia and acute angle-closure following drugs may interact with thiazide diuretics. amounts. Natriuresis may be accompanied by some glaucoma. Symptoms include acute onset of loss of potassium and bicarbonate. Alcohol, Barbiturates, or Narcotics: Potentiation decreased visual acuity or ocular pain and typically of orthostatic hypotension may occur. After oral use diuresis begins within 2 hours, occur within hours to weeks of drug initiation. Antidiabetic Drugs (Oral Agents and Insulin): peaks in about 4 hours and lasts about 6 to 12 Untreated acute angle-closure glaucoma can lead to Dosage adjustment of the antidiabetic drug may be hours. permanent vision loss. The primary treatment is to required. Pharmacokinetics and Metabolism: Hydro ­ discontinue hydrochlorothiazide as rapidly as possi­ chlorothiazide is not metabolized but is eliminated ble. Prompt medical or surgical treatments may Other Antihypertensive Drugs: Additive effect or rapidly by the kidney. When plasma levels have been need to be considered if the intraocular pressure potentiation. followed for at least 24 hours, the plasma half-life remains uncontrolled. Risk factors for developing Cholestyramine and Colestipol Resins: has been observed to vary between 5.6 and 14.8 acute angle-closure glaucoma may include a history Absorption of hydrochlorothiazide is impaired in the hours. At least 61% of the oral dose is eliminated of sulfonamide or penicillin allergy. presence of anionic exchange resins. Single doses unchanged within 24 hours. Hydro chlorothiazide of either cholestyramine or colestipol resins bind the crosses the placental but not the blood-brain barrier PRECAUTIONS: General: All patients receiving hydrochlorothiazide and reduce its absorption from and is excreted in breast milk. diuretic therapy should be observed for evidence of the gastrointestinal tract by up to 85% and 43%, fluid or electrolyte imbalance: namely, hyponatrem­ respectively. INDICATIONS AND USAGE: Hydrochlorothiazide ia, hypochloremic alkalosis, and hypokalemia. Corticosteroids, ACTH: Intensified electrolyte tablets are indicated as adjunctive therapy in edema Serum and urine electrolyte determinations are par­ depletion, particularly hypokalemia. associated with congestive heart failure, hepatic cir­ ticularly important when the patient is vomiting rhosis, and corticosteroid and estrogen therapy. excessively or receiving parenteral fluids. Warning Pressor Amines (e.g., Norepinephrine): Possible Hydrochlorothiazide tablets have also been found signs or symptoms of fluid and electrolyte imbal­ decreased response to pressor amines but not suffi­ useful in edema due to various forms of renal dys­ ance, irrespective of cause, include dryness of cient to preclude their use. function such as nephrotic syndrome, acute mouth, thirst, weakness, lethargy, drowsiness, rest­ Skeletal Muscle Relaxants, Nondepolarizing glomerulonephritis, and chronic renal failure. lessness, confusion, seizures, muscle pains or (e.g., Tubocurarine): Possible increased respon­ Hydrochlorothiazide tablets are indicated in the cramps, muscular fatigue, hypotension, oliguria, siveness to the muscle relaxant. management of hypertension either as the sole ther­ tachycardia, and gastrointestinal disturbances such Lithium: Generally should not be given with diuret­ apeutic agent or to enhance the effectiveness of as nausea and vomiting. ics. Diuretic agents reduce the renal clearance of other antihypertensive drugs in the more severe Hypokalemia may develop, especially with brisk lithium and add a high risk of lithium toxicity. Refer to forms of hypertension. diuresis, when severe cirrhosis is present or after the package insert for lithium preparations before Use in Pregnancy: Routine use of diuretics during prolonged therapy. use of such preparations with hydrochlorothiazide. normal pregnancy is inappropriate and exposes Interference with adequate oral electrolyte intake Non-Steroidal Anti-Inflammatory Drugs: In mother and fetus to unnecessary hazard. Diuretics will also contribute to hypokalemia. Hypokalemia some patients, the administration of a non-steroidal do not prevent development of toxemia of
Recommended publications
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972
    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Southwest Journal of Pulmonary and Critical Care/2017/Volume 15 100 September 2017 Critical Care Case of the Month James T. Dean
    September 2017 Critical Care Case of the Month James T. Dean III, MD Tyler R. Shackelford, DO Michel Boivin, MD Division of Pulmonary, Critical Care and Sleep Medicine University of New Mexico School of Medicine Albuquerque, NM USA A 73-year-old man presented with a three-day history of diffuse abdominal pain, decreased urine output, nausea and vomiting. His past medical history included diabetes, coronary artery disease, hypertension and chronic back pain. The patient reported being started on hydrochlorothiazide, furosemide, pregabalin and diclofenac within the last week in addition to his long-standing metformin prescription. Initial vitals were significant for tachypnea, tachycardia to 120 bpm, hypothermia to 35ºC and hypotension with a blood pressure of 70/40 mm Hg. Physical exam was remarkable for bilateral lung wheezing and significant respiratory distress. Laboratory examination was concerning for a pH of 6.85, pCO2 of < 5mmHg, serum lactate of 27mmol/l, WBC of 15.6 x106 cells/cc and a serum creatinine of 8.36 mg/dl. A chest X-ray showed evidence of mild pulmonary edema and a CT of the abdomen did not show any acute pathology. What is the most likely etiology of the patient’s severe acidosis? 1. Diabetic ketoacidosis 2. Ethylene glycol poisoning 3. Metformin-associated lactic acidosis 4. Septic shock Southwest Journal of Pulmonary and Critical Care/2017/Volume 15 100 Correct! 3. Metformin-associated lactic acidosis The most likely cause of the acidosis in this situation is metformin-induced lactic acidosis (1). The patient was intubated for respiratory failure secondary to severe non- compensated metabolic acidosis and shortly thereafter was started on maximal pressor support with norepinephrine, vasopressin, epinephrine and phenylephrine.
    [Show full text]
  • Comparing the Efficacy of Angiotensin Converting Enzyme In- Hibitors with Calcium Channel Blockers on the Treatment of Di- Abetic Nephropathy: a Meta-Analysis
    Iran J Public Health, Vol. 48, No.2, Feb 2019, pp.189-197 Review Article Comparing the Efficacy of Angiotensin Converting Enzyme In- hibitors with Calcium Channel Blockers on the Treatment of Di- abetic Nephropathy: A Meta-Analysis *Zhaowei ZHANG 1, Chunlin CHEN 2, Shiwen LV 1, Yalan ZHU 1, Tianzi FANG 1 1. Department of Pharmacy, Jin Hua Municipal Central Hospital, Jin Hua 32100, China 2. College of Chemistry and Bio-Engineering, Yi Chun University, Yi Chun 336000, China *Corresponding Author: Email: [email protected] (Received 21 Mar 2018; accepted 11 Jun 2018) Abstract Background: The angiotensin-converting enzyme inhibitors (ACEIs) could improve the symptoms of diabetic nephropathy. Whether the calcium channel blockers (CCBs) could be as effective as ACEIs on treating diabetic nephropathy is controversial. Here, we aimed to compare the efficacy of ACEIs with CCBs on the treatment of diabetic nephropathy by performing a meta-analysis of randomized controlled trials (RCTs). Methods: The Pubmed, Medline, Embase and The Cochrane Database were searched up to July 2017 for eli- gible randomized clinical trials studies. Effect sizes were summarized as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (P-value<0.05). Results: Seven RCTs involving 430 participants comparing ACEIs with CCBs were included. No benefit was seen in comparative group of ACEIs on systolic blood pressure(SBP) (MD=1.05 mmHg; 95% CI: -0.97 to 3.08, P=0.31), diastolic blood pressure (DBP) (MD= -0.34 mmHg; 95% CI: -1.2 to 0.51, P=0.43), urinary al- bumin excretion rates (UAER) (MD=1.91μg/min; 95% CI: -10.3 to 14.12, P=0.76), 24-h urine protein (24-UP) (SMD=-0.26; 95%CI: -0.55 to 0.03, P=0.08), glomerular filtration rate (GFR) (SMD=0.01; 95% CI: -0.38 to 0.41, P=0.95).
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Spironolactone Therapy in Infants with Congestive Heart Failure Secondary to Congenital Heart Disease
    Arch Dis Child: first published as 10.1136/adc.56.12.934 on 1 December 1981. Downloaded from Archives of Disease in Childhood, 1981, 56, 934-938 Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease SUSAN M HOBBINS, RODNEY S FOWLER, RICHARD D ROWE, AND ANDREW G KOREY Division of Cardiology, Department ofPaediatrics, Hospital for Sick Children, Toronto, and Department ofPaediatrics, University of Toronto, Canada SUMMARY The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P< 01) and respiratory rate (P< 0 05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spiro- nolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure. Spironolactone, a pharmacological antagonist of the We excluded or withdrew from the study any adrenal mineralocorticoid,l has been used for some infant in whom any of the following was present copyright. years in the treatment of congestive heart failure or developed. (1) Renal disease or dysfunction, as (CHF). By competitively binding to specific nuclear shown by blood urea nitrogen >8-925 mmol/l macromolecules in the distal convoluted renal (25 mg/100ml) or hepatic disease or dysfunction.
    [Show full text]
  • Actual Place of Diuretics in Hypertension Treatment
    Mini Review J Cardiol & Cardiovasc Ther Volume 3 Issue 4 - March 2017 Copyright © All rights are reserved by Farouk Abcha DOI: 10.19080/JOCCT.2017.03.555616 Actual Place of Diuretics in Hypertension Treatment Farouk Abcha, Marouane Boukhris*, Zied Ibn Elhadj, Lobna Laroussi, Faouzi Addad, Afef Ben Halima and Salem Kachboura Cardiology Department of Abderrahmen Mami Hospital, University of Tunis El Manar, Tunisia Submission: February 03, 2017; Published: March 07, 2017 *Corresponding author: Marouane Boukhris, Cardiology Department of Abderrahmen Mami Hospital, Ariana, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia, Tel: ; Email: Abstract Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment. In the current editorial, we assessed the actual place of different diuretics in the hypertension guidelines focusing on the concept of tailored approach in prescribing them for hypertensive patients. Keywords: Diuretics; Hypertension; Hydrochlorothiazide; Indapamide; Guidelines Introduction Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment [1]. Indeed, they are the second most commonly prescribed class of antihypertensive medication. For instance, 12% of US adults were prescribed a diuretic, and the relative increase in prescriptions from 1999 through 2012 was 1.4 [2].
    [Show full text]
  • WHO Model List (Revised April 2003) Explanatory Notes
    13th edition (April 2003) Essential Medicines WHO Model List (revised April 2003) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings. When the strength of a drug is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as". The square box symbol (? ) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]